FDA shifting user fees to safety surveillance

As the government enters the nineteenth day of a partial shutdown, FDA is taking steps to focus its dwindling funds on “key consumer protection functions,” FDA Commissioner Scott Gottlieb announced in a tweet.

“One action we’ll be taking is to re-allocate user fee money from certain pre-market drug review work to post market drug safety surveillance,” he said...